Cargando…
S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428351/ http://dx.doi.org/10.1097/01.HS9.0000967540.46956.59 |
| _version_ | 1785090447844048896 |
|---|---|
| author | Hochhaus, Andreas Burchert, Andreas Saußele, Susanne Baerlocher, Gabriela M Mayer, Jiri Brümmendorf, Tim H La Rosee, Paul Heim, Dominik Krause, Stefan W Le Coutre, Philipp Fabisch, Christian Rinke, Jenny Lange, Thoralf Fabarius, Alice Lorch, Marcel Hänel, Mathias Stegelmann, Frank Franke, Georg-Nikolaus Radsak, Markus Kunzmann, Volker Himsel, Danny Kohn, Denise Lang, Thomas Hehlmann, Rüdiger Ernst, Thomas Pfirrmann, Markus |
| author_facet | Hochhaus, Andreas Burchert, Andreas Saußele, Susanne Baerlocher, Gabriela M Mayer, Jiri Brümmendorf, Tim H La Rosee, Paul Heim, Dominik Krause, Stefan W Le Coutre, Philipp Fabisch, Christian Rinke, Jenny Lange, Thoralf Fabarius, Alice Lorch, Marcel Hänel, Mathias Stegelmann, Frank Franke, Georg-Nikolaus Radsak, Markus Kunzmann, Volker Himsel, Danny Kohn, Denise Lang, Thomas Hehlmann, Rüdiger Ernst, Thomas Pfirrmann, Markus |
| author_sort | Hochhaus, Andreas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428351 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283512023-08-17 S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. Hochhaus, Andreas Burchert, Andreas Saußele, Susanne Baerlocher, Gabriela M Mayer, Jiri Brümmendorf, Tim H La Rosee, Paul Heim, Dominik Krause, Stefan W Le Coutre, Philipp Fabisch, Christian Rinke, Jenny Lange, Thoralf Fabarius, Alice Lorch, Marcel Hänel, Mathias Stegelmann, Frank Franke, Georg-Nikolaus Radsak, Markus Kunzmann, Volker Himsel, Danny Kohn, Denise Lang, Thomas Hehlmann, Rüdiger Ernst, Thomas Pfirrmann, Markus Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428351/ http://dx.doi.org/10.1097/01.HS9.0000967540.46956.59 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Hochhaus, Andreas Burchert, Andreas Saußele, Susanne Baerlocher, Gabriela M Mayer, Jiri Brümmendorf, Tim H La Rosee, Paul Heim, Dominik Krause, Stefan W Le Coutre, Philipp Fabisch, Christian Rinke, Jenny Lange, Thoralf Fabarius, Alice Lorch, Marcel Hänel, Mathias Stegelmann, Frank Franke, Georg-Nikolaus Radsak, Markus Kunzmann, Volker Himsel, Danny Kohn, Denise Lang, Thomas Hehlmann, Rüdiger Ernst, Thomas Pfirrmann, Markus S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. |
| title | S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. |
| title_full | S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. |
| title_fullStr | S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. |
| title_full_unstemmed | S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. |
| title_short | S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. |
| title_sort | s157: nilotinib vs. nilotinib + peg-interferon αlpha induction and nilotinib or peg-interferon αlpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. the tiger trial. |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428351/ http://dx.doi.org/10.1097/01.HS9.0000967540.46956.59 |
| work_keys_str_mv | AT hochhausandreas s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT burchertandreas s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT saußelesusanne s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT baerlochergabrielam s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT mayerjiri s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT brummendorftimh s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT laroseepaul s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT heimdominik s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT krausestefanw s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT lecoutrephilipp s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT fabischchristian s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT rinkejenny s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT langethoralf s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT fabariusalice s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT lorchmarcel s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT hanelmathias s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT stegelmannfrank s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT frankegeorgnikolaus s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT radsakmarkus s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT kunzmannvolker s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT himseldanny s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT kohndenise s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT langthomas s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT hehlmannrudiger s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT ernstthomas s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial AT pfirrmannmarkus s157nilotinibvsnilotinibpeginterferonalphainductionandnilotiniborpeginterferonalphamaintenancetherapyfornewlydiagnosedchronicmyeloidleukemiapatientsthetigertrial |